Matches in Nanopublications for { ?s ?p "[MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 11 of
11
with 100 items per page.
- NP554584.RAUTTKyNG01rs8_l57DqN1rgrSvm383PY6AVIZmLJYFg4130_assertion description "[MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP554584.RAUTTKyNG01rs8_l57DqN1rgrSvm383PY6AVIZmLJYFg4130_provenance.
- NP363333.RANr15-2WbscHdbgcDutH8Z9uZRYk1Cy0cg73wwKKYW50130_assertion description "[MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP363333.RANr15-2WbscHdbgcDutH8Z9uZRYk1Cy0cg73wwKKYW50130_provenance.
- assertion description "[MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP551069.RA4mK2iuBp4clTwOUG3bFjZfkwkE_Gn5ev8VGwtqh1EKM130_assertion description "[MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP551069.RA4mK2iuBp4clTwOUG3bFjZfkwkE_Gn5ev8VGwtqh1EKM130_provenance.
- NP1312058.RA4hJbAW2ZQ-Y0zTzJcH6OIirEj7xoHgZzRqYRGNXOpVA130_assertion description "[MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1312058.RA4hJbAW2ZQ-Y0zTzJcH6OIirEj7xoHgZzRqYRGNXOpVA130_provenance.
- NP1312059.RA-4eJvj-1SiqR-BgGTBX_t7AP8ePVWHmhFouNjYj7Pto130_assertion description "[MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1312059.RA-4eJvj-1SiqR-BgGTBX_t7AP8ePVWHmhFouNjYj7Pto130_provenance.
- NP1312061.RA_r5JO8Vl6ftxmu3twLK-YIiuzqaHhfbS1S2lxLR5KQA130_assertion description "[MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1312061.RA_r5JO8Vl6ftxmu3twLK-YIiuzqaHhfbS1S2lxLR5KQA130_provenance.
- NP1312062.RA68X7q-9d_ONznzF3td_74GWCHOzzcIK0p05Iroje5kA130_assertion description "[MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1312062.RA68X7q-9d_ONznzF3td_74GWCHOzzcIK0p05Iroje5kA130_provenance.